Live Analyst Rating Changes 8035 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Justin Bowers
DB
Justin Bowers
Deutsche Bank
Wall Street Analyst
★★★★☆
#301
on 13Foresight · ranked by our own returns
76%
Success Rate
+13.1%
Average Return
16 of 21 calls profitable · +3.2% vs benchmark
📈 Across the calls we could measure, roughly 76% of Justin Bowers's ratings turned a profit when each position was held for 1 year — averaging +13.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

12 Buy 11 Hold 0 Sell
Justin's Stock Coverage 17 ratings · 2026-07-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
TMO
Thermo Fisher
 Jul 09, 2026 BUY Strong Buy
+11.5% avg upside
38 analysts
$630.00
19.48% Upside
 +0.4%
TECH
Bio-Techne
 Jun 26, 2026 HOLD Buy
+17.0% avg upside
21 analysts
$73.00
2.32% Upside
 +0.4%
ICLR
Icon
 Jun 25, 2026 BUY Strong Buy
+11.5% avg upside
25 analysts
$188.00
12.16% Upside
 +4.2%
TXG
10x Genomics
 May 08, 2026 HOLD Buy
-30.7% avg upside
18 analysts
$23.00
46.21% Downside
 +97.8%
CON
Concentra Group Holdings Parent, Inc.
 May 08, 2026 BUY Strong Buy
-0.3% avg upside
10 analysts
$32.00
1.36% Upside
 +31.8%
MRVI
Maravai Lifesciences Holdings
 May 08, 2026 BUY Strong Buy
+134.3% avg upside
17 analysts
$6.00
1.47% Downside
 +25.6%
FTRE
Fortrea Holdings Inc.
 May 07, 2026 HOLD Buy
-18.4% avg upside
11 analysts
$14.00
21.08% Downside
 +13.5%
WAT
Waters
 May 07, 2026 HOLD Strong Buy
+0.2% avg upside
30 analysts
$350.00
7.00% Downside
 +7.4%
WST
West Pharmaceutical Services
 Feb 13, 2026 BUY Strong Buy
+0.7% avg upside
17 analysts
$315.00
11.00% Downside
 +41.3%
DHR
Danaher
 Jan 29, 2026 BUY Strong Buy
+8.5% avg upside
45 analysts
$270.00
35.55% Upside
 -9.0%
CRL
Charles River Labs
 Aug 07, 2025 BUY Strong Buy
-10.2% avg upside
34 analysts
$185.00
20.79% Downside
 +55.8%
IQV
IQVIA Holdings
 Jul 29, 2025 BUY Strong Buy
+8.5% avg upside
38 analysts
$220.00
5.78% Upside
 +7.4%
MEDP
Medpace Holdings
 Jul 23, 2025 HOLD Buy
-23.7% avg upside
16 analysts
$430.00
20.05% Downside
 +21.9%
RGEN
Repligen
 Aug 16, 2024 BUY Strong Buy
+18.8% avg upside
25 analysts
$175.00
21.42% Upside
 -15.7%
AVTR
Avantor
 Jul 26, 2024 HOLD Buy
+39.2% avg upside
26 analysts
$25.00
140.52% Upside
 -44.5%
EHC
Encompass Health
 Sep 16, 2019 HOLD Strong Buy
+0.9% avg upside
22 analysts
$70.00
36.45% Downside
 +2.3%
ILMN
Illumina
 Jan 17, 2014 BUY Buy
-19.1% avg upside
30 analysts
$140.00
26.49% Downside
 +34.8%
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Justin Bowers — Frequently Asked Questions
How accurate are Justin Bowers's stock ratings?
Based on the calls 13Foresight could measure, about 76% of Justin's ratings were profitable over a one-year hold, with an average return of +12.8% per rating, or +2.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Justin ranked on 13Foresight?
Justin Bowers is currently ranked #301 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Justin cover?
Justin most recently has ratings on TMO, TECH, ICLR, TXG, CON, MRVI, FTRE, WAT, WST, DHR, CRL, IQV and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.